Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock Has Average Target Price of $6.23

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have earned a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $6.23.

A number of equities analysts have recently weighed in on IRWD shares. Weiss Ratings raised shares of Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Wall Street Zen downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 5th. Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Finally, Jefferies Financial Group raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research note on Friday, September 25th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IRWD. DGS Capital Management LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth $35,000. Principal Financial Group Inc. acquired a new position in Ironwood Pharmaceuticals in the first quarter valued at $40,000. Y Intercept Hong Kong Ltd acquired a new position in Ironwood Pharmaceuticals in the first quarter valued at $47,000. Bull Harbor Capital LLC acquired a new position in Ironwood Pharmaceuticals in the first quarter valued at $48,000. Finally, Chicago Partners Investment Group LLC acquired a new position in Ironwood Pharmaceuticals in the first quarter valued at $65,000.

Ironwood Pharmaceuticals Trading Down 7.2%

Ironwood Pharmaceuticals stock opened at $3.50 on Tuesday. The stock has a 50-day moving average price of $4.10 and a 200 day moving average price of $3.97. Ironwood Pharmaceuticals has a 52 week low of $1.43 and a 52 week high of $5.78. The stock has a market cap of $578.34 million, a PE ratio of 4.55 and a beta of 0.21.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%. The firm had revenue of $113.04 million during the quarter, compared to analysts’ expectations of $114.84 million. On average, equities analysts predict that Ironwood Pharmaceuticals will post 1.10 EPS for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused biopharmaceutical company that discovers, develops, and commercializes medicines for gastrointestinal diseases. The company concentrates on conditions affecting the digestive system, including disorders with substantial unmet medical needs.

Ironwood’s principal commercial product is LINZESS (linaclotide), a prescription treatment for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. In the United States, LINZESS is marketed through a collaboration with AbbVie, while it is marketed in many international markets under the name CONSTELLA through a collaboration with the healthcare business of AstraZeneca and other regional partners.

Founded in 1998 and headquartered in Boston, Massachusetts, Ironwood has expanded its development activities through internal research, partnerships, and acquisitions.